ArticleThe Journal of clinical endocrinology and metabolism2025
Central Precocious Puberty in Males, GnRH Analog Treated or Untreated, Did Not Impact Fertility and Health in Midadulthood.
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextThe long-term health consequences of idiopathic central precocious puberty (ICPP) in males, whether treated or untreated, are not well established.
objectiveTo evaluate general health and metabolic outcomes in adult men with a history of ICPP.
designRetrospective cohort study with age, birth year, and socioeconomic status-matched controls. PATIENTS: One hundred eighteen men aged 29 to 48 years with a history of ICPP (68 GnRH analog treated, 50 untreated) and 351 matched controls (204 matched to the treated group and 147 to the untreated group).
methodsData were extracted from the Clalit Health Services database and included demographics, medical history, medication records, anthropometric data, and laboratory results.
main outcome measuresPrevalence of reproductive issues, metabolic conditions (obesity, hypertension, hyperlipidemia, diabetes), osteoporosis, malignancy, and psychopathology.
resultsThe median age was 40 years in the treated and 44 years in the untreated ICPP group (P < .001). No significant differences were observed between treated and untreated groups in the prevalence of reproductive issues (11.8% vs 18.4%, P = .317), metabolic disorders (35.3% vs 34.7%, P = .946), cardiovascular conditions (16.2% vs 14.3%, P = .780), bone health problems (4.4% vs 4.1%, P = .931), psychopathology (19.1% vs 16.3%, P = .698), or malignancies (1.5% vs 8.2%, P = .160). Reproductive and health outcomes were also comparable between ICPP patients and their respective control groups, regardless of treatment history.
conclusionA history of ICPP in males, whether treated or untreated, does not appear to be associated with adverse long-term outcomes in reproductive, metabolic, emotional, or oncological health. Overall, adult men with prior ICPP exhibit similar health profiles to those of the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.